ME02944B - Novo antitelo protiv humanog ngf - Google Patents

Novo antitelo protiv humanog ngf

Info

Publication number
ME02944B
ME02944B MEP-2018-28A MEP201828A ME02944B ME 02944 B ME02944 B ME 02944B ME P201828 A MEP201828 A ME P201828A ME 02944 B ME02944 B ME 02944B
Authority
ME
Montenegro
Prior art keywords
novel anti
ngf antibody
human ngf
human
antibody
Prior art date
Application number
MEP-2018-28A
Other languages
German (de)
English (en)
French (fr)
Inventor
Masazumi Kamohara
Hirotsugu Tanaka
Yukari Koya
Jun Takasaki
Atsuo Yonezawa
Eiji Yoshimi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of ME02944B publication Critical patent/ME02944B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MEP-2018-28A 2011-08-11 2012-08-10 Novo antitelo protiv humanog ngf ME02944B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2011176209 2011-08-11
JP2011269215 2011-12-08
EP12821758.5A EP2743348B1 (en) 2011-08-11 2012-08-10 Novel anti-human ngf antibody
PCT/JP2012/070433 WO2013022083A1 (ja) 2011-08-11 2012-08-10 新規抗ヒトngf抗体

Publications (1)

Publication Number Publication Date
ME02944B true ME02944B (me) 2018-04-20

Family

ID=47668585

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2018-28A ME02944B (me) 2011-08-11 2012-08-10 Novo antitelo protiv humanog ngf

Country Status (28)

Country Link
US (2) US8986952B2 (me)
EP (1) EP2743348B1 (me)
JP (1) JP5376095B2 (me)
KR (1) KR101999867B1 (me)
CN (1) CN103748222B (me)
AR (1) AR087506A1 (me)
AU (1) AU2012293161B2 (me)
BR (1) BR112014002576B1 (me)
CA (1) CA2841181C (me)
CY (1) CY1119914T1 (me)
DK (1) DK2743348T3 (me)
EA (1) EA024292B1 (me)
ES (1) ES2663968T3 (me)
HR (1) HRP20180155T1 (me)
HU (1) HUE036079T2 (me)
IL (1) IL230797A (me)
IN (1) IN2014CN00614A (me)
LT (1) LT2743348T (me)
ME (1) ME02944B (me)
MX (1) MX351273B (me)
NO (1) NO2743348T3 (me)
PL (1) PL2743348T3 (me)
PT (1) PT2743348T (me)
RS (1) RS56876B1 (me)
SI (1) SI2743348T1 (me)
TW (1) TWI554519B (me)
WO (1) WO2013022083A1 (me)
ZA (1) ZA201400741B (me)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9783602B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトngf抗体
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
TWI706959B (zh) * 2015-05-22 2020-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類NGF抗體Fab片段
KR20180123559A (ko) * 2016-03-25 2018-11-16 아스텔라스세이야쿠 가부시키가이샤 PEG화 항인간 NGF 항체 Fab' 프래그먼트 함유 의약 조성물
CN109929035B (zh) * 2017-12-15 2022-06-28 安源医药科技(上海)有限公司 抗人ngf抗体及其制备方法和用途
JPWO2019221097A1 (ja) 2018-05-15 2021-05-27 アステラス製薬株式会社 抗ヒトngf抗体又はその抗原結合フラグメントを有効成分とする心房細動の抑制用医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0690132B1 (en) * 1993-03-11 2003-12-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-hiv monoclonal antibody
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2448956C (en) 2001-05-30 2017-10-03 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN102746399B (zh) 2002-12-24 2016-03-02 里纳特神经系统学公司 抗ngf抗体及其使用方法
WO2005019266A2 (en) 2003-07-15 2005-03-03 Amgen Inc. Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
BRPI0606933B8 (pt) 2005-01-24 2021-05-25 Cambridge Antibody Tech Limited membro de ligação específico isolado para fator de crescimento de nervos, molécula de anticorpo isolado, composição e uso de um membro de ligação específico
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
KR101709495B1 (ko) 2007-08-10 2017-02-23 리제너론 파아마슈티컬스, 인크. 인간 신경성장인자에 대한 고친화성 인간 항체
SI2206707T1 (sl) 2007-10-24 2014-11-28 Astellas Pharma Inc. Azolkarboksamidna spojina ali njena sol
EP2448970B1 (en) 2009-05-04 2014-07-09 Abbott Research B.V. Antibodies against nerve growth factor (ngf) with enhanced in vivo stability

Also Published As

Publication number Publication date
TWI554519B (zh) 2016-10-21
NO2743348T3 (me) 2018-06-09
WO2013022083A1 (ja) 2013-02-14
EP2743348A1 (en) 2014-06-18
KR20140047116A (ko) 2014-04-21
IL230797A0 (en) 2014-03-31
BR112014002576A2 (pt) 2021-01-12
HUE036079T2 (hu) 2018-06-28
AU2012293161A1 (en) 2014-02-06
TW201319086A (zh) 2013-05-16
EA024292B1 (ru) 2016-09-30
KR101999867B1 (ko) 2019-07-12
ZA201400741B (en) 2014-11-26
ES2663968T3 (es) 2018-04-17
CN103748222A (zh) 2014-04-23
US20140155582A1 (en) 2014-06-05
JPWO2013022083A1 (ja) 2015-03-05
MX2014001627A (es) 2014-05-28
BR112014002576B1 (pt) 2022-08-23
CN103748222B (zh) 2015-07-22
CY1119914T1 (el) 2018-06-27
IN2014CN00614A (me) 2015-04-03
US20150218265A1 (en) 2015-08-06
US8986952B2 (en) 2015-03-24
DK2743348T3 (en) 2018-02-26
CA2841181A1 (en) 2013-02-14
SI2743348T1 (en) 2018-04-30
AU2012293161B2 (en) 2017-04-27
EA201490433A1 (ru) 2014-05-30
PL2743348T3 (pl) 2018-04-30
HRP20180155T1 (hr) 2018-03-23
PT2743348T (pt) 2018-02-23
CA2841181C (en) 2022-01-25
EP2743348A4 (en) 2015-04-29
IL230797A (en) 2017-06-29
RS56876B1 (sr) 2018-04-30
MX351273B (es) 2017-10-06
AR087506A1 (es) 2014-03-26
JP5376095B2 (ja) 2013-12-25
LT2743348T (lt) 2018-05-10
EP2743348B1 (en) 2018-01-10

Similar Documents

Publication Publication Date Title
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
HK1248717A1 (zh) 異二聚體免疫球蛋白
IL259826A (en) Anti-alphabetatisiar antibody
ZA201400768B (en) Interleukin-31 monoclonal antibody
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
ZA201400741B (en) Novel anti-human ngf antibody
HK1199038A1 (en) Anti-human xcr1 antibodies xcr1
PT2695897T (pt) Novo anticorpo anti-receptor de il-23 humano
PT2796550T (pt) Novo anticorpo ctgf anti-humano
EP2769988A4 (en) ANTI-GAP43 ANTIBODY
EP2714074A4 (en) ANTIBODIES AGAINST EMR1